Abel Garcia-Garcia

Dr. Abel Garcia-Garcia

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2009 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
Mario Pérez-SayánsMario Pérez-Sayáns
Mario Pérez-Sayáns
JMJOSE MANUEL SOMOZA MARTÍN
JOSE MANUEL SOMOZA MARTÍN
FBFrancisco Barros
Francisco Barros
JRJosé Manuel Gándara Rey
José Manuel Gándara Rey
AGAbel Garcia-Garcia
Abel Garcia-Garcia

1 October 2015 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
ESEnrico Pierluigi Spugnini
Enrico Pierluigi Spugnini
Pierre SonveauxPierre Sonveaux
Pierre Sonveaux
CSChristian Stock
Christian Stock
Mario Pérez-SayánsMario Pérez-Sayáns
Mario Pérez-Sayáns
AMAngelo De Milito
Angelo De Milito
Stefano FaisStefano Fais
Stefano Fais

1 March 2011 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
APAlejandra Piñeiro-Aguilar
Alejandra Piñeiro-Aguilar
JMJOSE MANUEL SOMOZA MARTÍN
JOSE MANUEL SOMOZA MARTÍN
JGJosé M. Gandara-Rey
José M. Gandara-Rey
AGAbel Garcia-Garcia
Abel Garcia-Garcia

1 May 2007 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
LLLucía Lago-Méndez
Lucía Lago-Méndez
Marcio Diniz-FreitasMarcio Diniz-Freitas
Marcio Diniz-Freitas
CSCarmen Senra
Carmen Senra
FGFrancisco Gude-Sampedro
Francisco Gude-Sampedro
JRJosé Manuel Gándara Rey
José Manuel Gándara Rey
AGAbel Garcia-Garcia
Abel Garcia-Garcia

23 November 2014 in Journal of Clinical Periodontology
Verified
Journal Article
Closed access
PDF file
DTDaniel Thoma
Daniel Thoma
RHRobert Haas
Robert Haas
MTMarcin Tutak
Marcin Tutak
AGAbel Garcia-Garcia
Abel Garcia-Garcia
GSGian Pietro Schincaglia
Gian Pietro Schincaglia
CHChristoph H. F. Hämmerle
Christoph H. F. Hämmerle

26 March 2019 in Cancers
Verified
Journal Article
Open access
PDF file
SZSamuel Rodríguez Zorrilla
Samuel Rodríguez Zorrilla
Mario Pérez-SayánsMario Pérez-Sayáns
Mario Pérez-Sayáns
Stefano FaisStefano Fais
Stefano Fais
MLMariantonia Logozzi
Mariantonia Logozzi
MGMercedes Gallas-Torreira
Mercedes Gallas-Torreira
AGAbel Garcia-Garcia
Abel Garcia-Garcia
Background: To evaluate the relationship between the plasmatic CD63 and CAV1 positive exosome levels, in patients with OSCC before and after surgical treatment and to correlate it with their overall survival. Methods: A double-blind pilot study over 10 patients OSCC and T4 stage without distant metastases or local bone invasion has been performed. The average follow-up period was 37.64 months (34.3–40.84). We obtained 2 plasma tubes of 1 mL each before surgery and 7 days after surgery. Before performing the immunocapture-based analysis, EVs (Extracellular Vesicles) were isolated from the plasma and characterized with western blot analysis. Results: Mean values of CD63 positive plasmatic exosomes (EXO-CD63) after surgery decreased from 750.88 ± 286.67 to 541.71 ± 244.93 (p = 0.091). On the other hand, CAV-1 positive plasmatic exosomes (EXO-CAV-1) increased after surgery from 507 ± 483.39 to 1120.25 ± 1151.17 (p = 0.237). Patients with EXO-CD63 levels lower than the mean global value before the surgery had a survival of 36.04 months compared with the group with EXO-CD63 higher than the average who only survived 12.49 ± 1.67 months from the diagnosis, p = 0.225. When EXO-CAV-1 levels before surgery was lower than the average (813.94 ± 801.21) overall survival was 24.69 ± 22.23 months in contrast when it was higher that was only 11.64 months, p = 0.157. Patients with lower EXO-CD63 levels after surgery lived an average of 23.84 ± 23.9 months, while those with higher plasmatic levels of EXO-CD63 live 13.35 months, p = 0.808. When EXO-CAV-1 levels after surgery were lower, the average overall survival was 20.344 ± 15.40 months, in contrast when the EXO-CAV-1 levels were higher showing rather an estimate survival expectation of 1.64 months. Conclusions: Surgical treatment induced a dramatic reduction of the plasmatic levels of exosomes expressing CD63 as early as 1 week after resection. This first result suggests that the tumour mass is responsible of the high levels of circulating exosomes detected in cancer patients. At the same time point exosome expressing CAV-1 increased, possibly due to the inflammatory reaction immediately after surgery. Lastly, statistical analysis showed that lower levels of plasmatic exosomes both before and after surgery correlated with a better life expectancy of OSCC patients. Hopefully, this approach will prove useful in the clinical follow-up of cancer patients.